The MCAS POTS EDS Trifecta Is Not a Trend. It Is a Reckoning.
The MCAS POTS EDS Trifecta
By Maryann Walsh, RD
Key Takeaways
- The MCAS POTS EDS trifecta reflects decades of unanswered symptoms rather than a social media trend.
- Current diagnostic tools for MCAS often fail due to the lack of standardized and reliable markers.
- The overlap of MCAS, POTS, and EDS suggests shared underlying mechanisms affecting diagnosis.
- Ongoing research is addressing important questions about mast cell behavior, connective tissue, and microbiome roles.
- Recognizing the validity of symptoms is crucial; patients deserve serious consideration from clinicians.
Estimated reading time: 6 minutes
The surge of people identifying with histamine intolerance, Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and Ehlers-Danlos Syndrome (EDS) is not a social media phenomenon. It is not wellness culture gone too far. It is not patients self-diagnosing from Instagram reels.
It is decades of dismissed symptoms finally finding a framework.
I am a Registered Dietitian who specializes in this space. I work with these patients every single day. I am also one of them. When I say I am watching something significant unfold in real time, I need you to take that seriously.
What I See in My Practice — and in My Own Body
I have sat across from clients who have spent years — sometimes twenty or thirty years — cycling through specialists and leaving with nothing but a diagnosis of exclusion. Idiopathic fatigue. Functional GI disorder. Anxiety. Unexplained inflammation. Normal labs every time.
It was never fine. These were people with mast cells misfiring, connective tissue that could not hold steady, and autonomic nervous systems responding to the wrong signals at the wrong times. Because no single specialist owns all of those body systems, nobody connected the dots.
I lived that same experience. Fatigue that sleep never fixed. Digestive symptoms that followed no logical pattern. Reactions to foods I had eaten hundreds of times. For years I filed these things under that is just how I am. Even with clinical training, I could not assemble the pieces into a coherent picture for a long time. That is not a personal failure. That is a gap in the medical system.
Why Current Diagnostic Tests Are Still Failing MCAS Patients
Here is the honest clinical reality: reliable, standardized diagnostic tools for MCAS do not yet exist in the way we need them to.
Serum tryptase is frequently normal in MCAS patients. Tryptase elevation is more characteristic of systemic mastocytosis than of MCAS (Valent et al., 2020, Journal of Allergy and Clinical Immunology).
24-hour urine histamine and prostaglandin panels are valuable in theory but require strict collection protocols. Many commercial labs lack the sensitivity to detect the episodic, fluctuating mediator release that defines this condition.
Histamine blood levels are similarly unreliable. Histamine degrades rapidly, and timing a blood draw to an active reaction is nearly impossible in a standard clinical setting.
IgG food intolerance panels have limited evidence supporting their use as a diagnostic tool for MCAS or histamine intolerance (Stapel et al., 2008, Allergy). Yet this is often what patients are handed, because it is accessible and billable.
The proposed diagnostic criteria for MCAS require a constellation of multisystem symptoms, a response to mast cell mediator-targeting therapies, and at minimum one elevated mediator marker. That last requirement is where patients fall through. Their symptoms are real. Their response to treatment is real. Their labs are inconclusive.
This is not evidence that the condition does not exist. It is evidence that our biomarkers have not caught up to our clinical observations.
Why MCAS, POTS, and EDS Travel Together
The overlap between MCAS, POTS, and hypermobile Ehlers-Danlos Syndrome (hEDS) is not coincidental. It is increasingly recognized in the medical literature, though the mechanisms are still being mapped.
Connective tissue dysfunction in hEDS may compromise the integrity of blood vessel walls and the extracellular matrix surrounding mast cells, potentially altering mast cell behavior and mediator release. POTS — characterized by an abnormal heart rate response to positional changes — is found at disproportionately high rates in hEDS patients. Mast cell mediators including histamine are known to influence vascular tone and autonomic signaling (Shibao et al., 2005, Hypertension).
These are not three separate diagnoses that happen to co-occur. They appear to share underlying mechanistic pathways that we are only beginning to characterize.
Why I Am Still Confident We Are Getting Closer
The questions being asked now — about mast cell behavior, connective tissue and the autonomic nervous system, the microbiome’s role in histamine metabolism, and DAO enzyme genetics — are the right questions. Researchers are asking them with increasing rigor.
DAO enzyme activity and genetic variants in the AOC1 gene are being studied as contributors to histamine intolerance susceptibility (Maintz et al., 2011, Journal of Investigative Dermatology). The microbiome’s role in histamine production and degradation is a genuinely emerging area of research. Mast cell-literate clinicians — a specialty descriptor that barely existed a decade ago — are building dedicated practices.
The diagnostic picture is incomplete. But it is filling in. And in the meantime, clinical pattern recognition — the kind that comes from seeing hundreds of patients with overlapping presentations, and from being one of those patients yourself — is not nothing. Observation precedes mechanism. Description precedes biomarker. That is how medicine has always moved forward.
What I Want You to Take Away
If you have spent years being told your labs are normal while your body tells you otherwise — you are not imagining it. You are not anxious. You are not a hypochondriac who found a community online.
You may be presenting a clinical picture that medicine is still developing the tools to see clearly. That gap is a failure of the system, not a failure of your body to make sense.
For clinicians reading this: I am not asking you to diagnose MCAS without a workup. I am asking you to hold the possibility open. To recognize that a normal serum tryptase does not close the door. To refer to colleagues who specialize in this space.
The patients sitting in your office with idiopathic everything deserve better than a shrug and a six-month follow-up.
This post is for educational purposes only and is not a substitute for individualized medical or nutrition advice. If you suspect MCAS, POTS, EDS, or histamine intolerance, please seek evaluation from a qualified healthcare provider familiar with these conditions.
References:
- Maintz, L. et al. (2011). Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities. Journal of Investigative Dermatology, 131(10), 2171–2174.
- Molderings, G.J. et al. (2011). Mast cell activation disease: A concise practical guide. Journal of Hematology and Oncology, 4, 10.
- Shibao, C. et al. (2005). Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension, 45(3), 385–390.
- Stapel, S.O. et al. (2008). Testing for IgG4 against foods is not recommended as a diagnostic tool. Allergy, 63(7), 793–796.
- Valent, P. et al. (2020). Diagnosis and treatment of systemic mastocytosis. Journal of Allergy and Clinical Immunology, 145(4), 1134–1151.
